KEROS THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Jasbir Seehra

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jasbir Seehra, Ph.D.”): 28,980,411 for, 199,924 withheld, per its Form 8-K filed May 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 11,757,522 for, 95,841 withheld.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Julius Knowles

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Julius Knowles”): 21,464,815 for, 7,715,520 withheld, per its Form 8-K filed May 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 9,806,136 for, 29 against, 2,047,198 withheld.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Nima Farzan

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nima Farzan”): 22,751,167 for, 6,429,168 withheld, per its Form 8-K filed May 30, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 62 asset managers below reported 10,965,145 for, 29 against, 888,189 withheld.

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.

KEROS THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 28,988,355 for, 183,267 against — passed, per its Form 8-K filed May 30, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of KEROS THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, 209,361 for, 381 against); “To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.” (3 managers, 1,108,650 for); “To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.” (2 managers, 360,000 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 61 managers: 11,841,526 for, 11,808 against. Showing the 25 largest; see all in the interactive database.

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 55 managers: 680,000 for, 10,788,373 1 year, 94,799 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 90 managers: 13,906 for, 33,330,190 1 year, 20,996 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company s named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 7 managers: 290,162 1 year.

Institutional-manager reports, all 25 managers: 1,945,695 1 year.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.

KEROS THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2024”): 32,276,768 for, 1,439 against — passed, per its Form 8-K filed May 30, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2024 The Company's stockholders approved Proposal 2.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 11,863,468 for.

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.